AN2 Therapeutics, Inc. ANTX
AN2 Therapeutics, Inc. (Nasdaq: ANTX) is an infectious disease drug developer. Its lead program, Epetraborole, is in Phase 2 for Mycobacterium abscessus complex lung disease. Its next catalyst on record is Epetraborole: PV Phase 2 enrollment start (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Epetraborole — PV Phase 2 enrollment start (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Epetraborole | Mycobacterium abscessus complex lung disease (investigator-initiated Phase 2, OHSU) | small molecule | Phase 2 |
| AN2-502998 | Chronic Chagas disease | small molecule | Phase 1 |
| Epetraborole | Polycythemia vera (EBO-PV-201) | small molecule | Pre-clinical |
| Epetraborole | Acute melioidosis | small molecule | Pre-clinical |
| ENPP1 inhibitor | Solid tumors | small molecule | Pre-clinical |
Recent results and decisions
- Jun 4, 2026positive Phase 1 FIH study of oral AN2-502998 showed good tolerability with no dose-limiting toxicities and exposures at or above NHP efficacy thresholds; 28-day dosing eliminated parasites in 100% of naturally infected NHPs, durable through 4 months.
In the Phase 1 FIH study, AN2-502998 was generally well tolerated at exposure levels consistent with NHP efficacy thresholds, with no dose-limiting toxicities.
Filing - May 11, 2026started Randomized, double-blind, placebo-controlled Phase 2 investigator-initiated trial of epetraborole in M. abscessus lung disease commenced, with patient screening starting in March 2026.
Patient screening commenced in March 2026.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.